HOLOGIC INC (HOLX)

Data as of Apr 9, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch HOLX

See up to 3 months of HOLX. The 7-day demo opens the 1M and 3M ranges and puts HOLX on your watchlist.

Latest HOLX insider trades

Jan Verstreken - Officer
Derivative134,039 sh
Apr 7, 2026
Jan Verstreken - Officer
Derivative7,564 sh
Apr 7, 2026
Jan Verstreken - Officer
Derivative

About HOLOGIC INC (HOLX)

HOLOGIC INC is an SEC registrant, filing under CIK 0000859737, classified as x-ray apparatus and tubes and related irradiation apparatus. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for HOLX on EDGAR

HOLX Form 4 activity by transaction type, last 90 days

No Form 4 activity for HOLX in the last 90 days.

HOLX insider transactions (Form 4)

154

82 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 1 of 3.

Date	Insider	Transaction	Security	Shares	Price	Value
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Common Stock	134,039	-^{footnote F1,F2}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	7,564	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	12,490	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	13,971	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	15,387	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	29,002	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	12,509	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	17,831	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	19,327	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	20,056	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	18,698	-^{footnote F3}	-
Apr 7, 2026	Jan Verstreken - Officer	Grant or award	Performance Stock Units	31,409	-^{footnote F5}	-
Apr 7, 2026	Jan Verstreken - Officer	Derivative	Performance Stock Units	31,409	-^{footnote F5}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below. Footnote F5 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Common Stock	17,644^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,265	-^{footnote F4}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,865	-^{footnote F4}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	5,014	-^{footnote F4}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,538	-^{footnote F4}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	8,414	-^{footnote F4}	-
Apr 7, 2026	Brandon Schnittker - Officer	Grant or award	Performance Stock Units	8,432	-^{footnote F6}	-
Apr 7, 2026	Brandon Schnittker - Officer	Derivative	Performance Stock Units	8,432	-^{footnote F6}	-
Footnote F1 (shares): Includes 132 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Common Stock	41,462^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,804	-^{footnote F4}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	4,058	-^{footnote F4}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	10,028	-^{footnote F4}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	18,698	-^{footnote F4}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Grant or award	Performance Stock Units	22,598	-^{footnote F6}	-
Apr 7, 2026	Jennifer M. Schneiders - Officer	Derivative	Performance Stock Units	22,598	-^{footnote F6}	-
Footnote F1 (shares): Includes 144 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	23,767	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	23,775	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	21,743	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	25,070	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	28,047	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Common Stock	150,735^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	30,774	-^{footnote F4}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Grant or award	Performance Stock Units	42,707	-^{footnote F6}	-
Apr 7, 2026	Karleen Marie Oberton - Officer	Derivative	Performance Stock Units	42,707	-^{footnote F6}	-
Footnote F1 (shares): Includes 41,121 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Common Stock	77,694^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,972	-^{footnote F4}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	11,596	-^{footnote F4}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	25,070	-^{footnote F4}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	32,722	-^{footnote F4}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Grant or award	Performance Stock Units	46,154	-^{footnote F6}	-
Apr 7, 2026	Essex D. Mitchell - Officer	Derivative	Performance Stock Units	46,154	-^{footnote F6}	-
Footnote F1 (shares): Includes 84 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Common Stock	28,052	-^{footnote F1,F2}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,173	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	6,129	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	5,943	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	5,121	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	6,016	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	7,479	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	4,683	-^{footnote F3}	-
Apr 7, 2026	Anne M. Liddy - Officer	Grant or award	Performance Stock Units	3,452	-^{footnote F5}	-
Apr 7, 2026	Anne M. Liddy - Officer	Derivative	Performance Stock Units	3,452	-^{footnote F5}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below. Footnote F5 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Common Stock	23,026^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,490	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	5,349	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,899	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,509	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,505	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	2,844	-^{footnote F4}	-
Apr 7, 2026	Mark W. Horvath - Officer	Grant or award	Performance Stock Units	7,762	-^{footnote F6}	-
Apr 7, 2026	Mark W. Horvath - Officer	Derivative	Performance Stock Units	7,762	-^{footnote F6}	-
Footnote F1 (shares): Includes 4,605 performance stock units/restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Walt Diana de - Officer	Derivative	Common Stock	7,603	-^{footnote F1,F2}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,523	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,322	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,055	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Common Stock	25,784	-^{footnote F1,F2}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	1,500	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,816	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,551	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,293	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,210	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F3}	-
Apr 7, 2026	Amy McBride Wendell - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F3}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below.
Apr 7, 2026	Stacey D. Stewart - Director	Derivative	Common Stock	8,358^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Stacey D. Stewart - Director	Derivative	Non-qualified Stock Option (Right to Buy)	768	-^{footnote F4}	-
Apr 7, 2026	Stacey D. Stewart - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,210	-^{footnote F4}	-
Apr 7, 2026	Stacey D. Stewart - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F4}	-
Apr 7, 2026	Stacey D. Stewart - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F4}	-
Footnote F1 (shares): Includes 3,436 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below.
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Common Stock	50,526	-^{footnote F1,F2}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,816	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,551	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,523	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,322	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,055	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,293	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,210	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F3}	-
Apr 7, 2026	Christiana Stamoulis - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F3}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below.
Apr 7, 2026	Nanaz Mohtashami - Director	Derivative	Common Stock	7,371	-^{footnote F1,F2}	-
Apr 7, 2026	Nanaz Mohtashami - Director	Derivative	Non-qualified Stock Option (Right to Buy)	2,141	-^{footnote F3}	-
Apr 7, 2026	Nanaz Mohtashami - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F3}	-
Apr 7, 2026	Nanaz Mohtashami - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F3}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below.
Apr 7, 2026	Wayde D. McMillan - Director	Derivative	Common Stock	4,932	-^{footnote F1,F2}	-
Apr 7, 2026	Wayde D. McMillan - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,171	-^{footnote F3}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): For Footnote (3), see Remarks below.
Apr 7, 2026	Martin D. Madaus - Director	Derivative	Common Stock	5,396	-^{footnote F1,F2}	-
Apr 7, 2026	Martin D. Madaus - Director	Derivative	Common Stock	5,445	-^{footnote F1,F3}	-
Apr 7, 2026	Martin D. Madaus - Director	Derivative	Non-qualified Stock Option (Right to Buy)	1,016	-^{footnote F4}	-
Apr 7, 2026	Martin D. Madaus - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Footnote F4 (price): For Footnote (4), see Remarks below.
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Common Stock	1,423,837^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Common Stock	1,146,829	-^{footnote F2,F4}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	160,565	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	159,339	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	768,639	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	151,071	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	152,529	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	123,801	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	118,877	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	106,300	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	117,829	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	117,801	-^{footnote F5}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Grant or award	Performance Stock Units	190,400	-^{footnote F7}	-
Apr 7, 2026	Stephen P. Macmillan - Officer	Derivative	Performance Stock Units	190,400	-^{footnote F7}	-
Footnote F1 (shares): Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Footnote F5 (price): For Footnote (5), see Remarks below. Footnote F7 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Common Stock	16,146^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	2,012	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,523	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,322	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,055	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,293	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,210	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F4}	-
Apr 7, 2026	Ludwig Hantson - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F4}	-
Footnote F1 (shares): Includes 3,695 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below.
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,396	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	6,523	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	7,322	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,055	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Common Stock	6,626	-^{footnote F1,F2}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Common Stock	15,370	-^{footnote F1,F3}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,293	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,210	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	4,536	-^{footnote F4}	-
Apr 7, 2026	Charles J. Dockendorff - Director	Derivative	Non-qualified Stock Option (Right to Buy)	5,535	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR Footnote F3 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Footnote F4 (price): For Footnote (4), see Remarks below.
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Common Stock	17,964^{footnote F1}	-^{footnote F2,F3}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	10,861	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	7,505	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	7,132	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,382	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,509	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Non-qualified Stock Option (Right to Buy)	3,505	-^{footnote F4}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Grant or award	Performance Stock Units	5,665	-^{footnote F6}	-
Apr 7, 2026	Benjamin Jordan Cohn - Officer	Derivative	Performance Stock Units	5,665	-^{footnote F6}	-
Footnote F1 (shares): Includes 80 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR Footnote F4 (price): For Footnote (4), see Remarks below. Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR
Feb 27, 2026	Anne M. Liddy - Officer	Tax withholding / forfeiture	Common Stock	185^{footnote F1}	$75.36	$14K
Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.
Feb 26, 2026	Amy McBride Wendell - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Stacey D. Stewart - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Christiana Stamoulis - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Nanaz Mohtashami - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Wayde D. McMillan - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Martin D. Madaus - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Ludwig Hantson - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 26, 2026	Charles J. Dockendorff - Director	Grant or award	Common Stock	3,190^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.
Feb 10, 2026	Mark W. Horvath - Officer	Tax withholding / forfeiture	Common Stock	113^{footnote F1}	$75.15	$8K
Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.
Jan 30, 2026	Walt Diana de - Officer	Tax withholding / forfeiture	Common Stock	4,416^{footnote F1}	$74.93	$331K
Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.
Dec 12, 2025	Brandon Schnittker - Officer	Tax withholding / forfeiture	Common Stock	90^{footnote F1}	$75.00	$7K
Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Recent HOLX Form 8-K filings

Read HOLX company news

Apr 7, 2026Item 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01

Read the filing on SEC EDGAR

Apr 6, 2026Item 5.02, 8.01, 9.01

Read the filing on SEC EDGAR

Congress trades in HOLX

All congress trades

Stock trades in HOLX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Laura FriedmanDemocrat, CA-30	Sale (partial)

HOLX insider trading FAQ

What is the latest insider trade for HOLX?

HOLOGIC INC (HOLX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-09. The full record for HOLX runs to 82 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying HOLX stock?

No insider purchases of HOLX were filed in the last 90 days.

How many insiders are selling HOLX stock?

No insider sales of HOLX were filed in the last 90 days. 5 sales are on record for this company.

Where can I see HOLX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects HOLX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Apr 9, 2026 - Jan Verstreken view on EDGAR
Apr 9, 2026 - Brandon Schnittker view on EDGAR
Apr 9, 2026 - Jennifer M. Schneiders view on EDGAR
Apr 9, 2026 - Karleen Marie Oberton view on EDGAR
Apr 9, 2026 - Essex D. Mitchell view on EDGAR
Apr 9, 2026 - Anne M. Liddy view on EDGAR
Apr 9, 2026 - Mark W. Horvath view on EDGAR
Apr 9, 2026 - Walt Diana de view on EDGAR
Apr 9, 2026 - Amy McBride Wendell view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where HOLX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow HOLX with a 7-day demo

HOLX on your watchlist
Every HOLX Form 4 filing on record
Up to 3 months of HOLX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Common Stock

134,039

-^{footnote F1,F2}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

7,564

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

12,490

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

13,971

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

15,387

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

29,002

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

12,509

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

17,831

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

19,327

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

20,056

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

18,698

-^{footnote F3}

Apr 7, 2026

Jan Verstreken - Officer

Grant or award

Performance Stock Units

31,409

-^{footnote F5}

Apr 7, 2026

Jan Verstreken - Officer

Derivative

Performance Stock Units

31,409

-^{footnote F5}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.
Footnote F5 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Common Stock

17,644^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,265

-^{footnote F4}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,865

-^{footnote F4}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

5,014

-^{footnote F4}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,538

-^{footnote F4}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

8,414

-^{footnote F4}

Apr 7, 2026

Brandon Schnittker - Officer

Grant or award

Performance Stock Units

8,432

-^{footnote F6}

Apr 7, 2026

Brandon Schnittker - Officer

Derivative

Performance Stock Units

8,432

-^{footnote F6}

Footnote F1 (shares): Includes 132 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Common Stock

41,462^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,804

-^{footnote F4}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

4,058

-^{footnote F4}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

10,028

-^{footnote F4}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

18,698

-^{footnote F4}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Grant or award

Performance Stock Units

22,598

-^{footnote F6}

Apr 7, 2026

Jennifer M. Schneiders - Officer

Derivative

Performance Stock Units

22,598

-^{footnote F6}

Footnote F1 (shares): Includes 144 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

23,767

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

23,775

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

21,743

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

25,070

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

28,047

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Common Stock

150,735^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

30,774

-^{footnote F4}

Apr 7, 2026

Karleen Marie Oberton - Officer

Grant or award

Performance Stock Units

42,707

-^{footnote F6}

Apr 7, 2026

Karleen Marie Oberton - Officer

Derivative

Performance Stock Units

42,707

-^{footnote F6}

Footnote F1 (shares): Includes 41,121 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Common Stock

77,694^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,972

-^{footnote F4}

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

11,596

-^{footnote F4}

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

25,070

-^{footnote F4}

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

32,722

-^{footnote F4}

Apr 7, 2026

Essex D. Mitchell - Officer

Grant or award

Performance Stock Units

46,154

-^{footnote F6}

Apr 7, 2026

Essex D. Mitchell - Officer

Derivative

Performance Stock Units

46,154

-^{footnote F6}

Footnote F1 (shares): Includes 84 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Common Stock

28,052

-^{footnote F1,F2}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,173

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

6,129

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

5,943

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

5,121

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

6,016

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

7,479

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

4,683

-^{footnote F3}

Apr 7, 2026

Anne M. Liddy - Officer

Grant or award

Performance Stock Units

3,452

-^{footnote F5}

Apr 7, 2026

Anne M. Liddy - Officer

Derivative

Performance Stock Units

3,452

-^{footnote F5}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.
Footnote F5 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Common Stock

23,026^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,490

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

5,349

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,899

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,509

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,505

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

2,844

-^{footnote F4}

Apr 7, 2026

Mark W. Horvath - Officer

Grant or award

Performance Stock Units

7,762

-^{footnote F6}

Apr 7, 2026

Mark W. Horvath - Officer

Derivative

Performance Stock Units

7,762

-^{footnote F6}

Footnote F1 (shares): Includes 4,605 performance stock units/restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Walt Diana de - Officer

Derivative

Common Stock

7,603

-^{footnote F1,F2}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,523

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,322

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,055

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Common Stock

25,784

-^{footnote F1,F2}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

1,500

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,816

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,551

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,293

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,210

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F3}

Apr 7, 2026

Amy McBride Wendell - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.

Apr 7, 2026

Stacey D. Stewart - Director

Derivative

Common Stock

8,358^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Stacey D. Stewart - Director

Derivative

Non-qualified Stock Option (Right to Buy)

768

-^{footnote F4}

Apr 7, 2026

Stacey D. Stewart - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,210

-^{footnote F4}

Apr 7, 2026

Stacey D. Stewart - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F4}

Apr 7, 2026

Stacey D. Stewart - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F4}

Footnote F1 (shares): Includes 3,436 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Common Stock

50,526

-^{footnote F1,F2}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,816

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,551

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,523

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,322

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,055

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,293

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,210

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F3}

Apr 7, 2026

Christiana Stamoulis - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.

Apr 7, 2026

Nanaz Mohtashami - Director

Derivative

Common Stock

7,371

-^{footnote F1,F2}

Apr 7, 2026

Nanaz Mohtashami - Director

Derivative

Non-qualified Stock Option (Right to Buy)

2,141

-^{footnote F3}

Apr 7, 2026

Nanaz Mohtashami - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F3}

Apr 7, 2026

Nanaz Mohtashami - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.

Apr 7, 2026

Wayde D. McMillan - Director

Derivative

Common Stock

4,932

-^{footnote F1,F2}

Apr 7, 2026

Wayde D. McMillan - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,171

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): For Footnote (3), see Remarks below.

Apr 7, 2026

Martin D. Madaus - Director

Derivative

Common Stock

5,396

-^{footnote F1,F2}

Apr 7, 2026

Martin D. Madaus - Director

Derivative

Common Stock

5,445

-^{footnote F1,F3}

Apr 7, 2026

Martin D. Madaus - Director

Derivative

Non-qualified Stock Option (Right to Buy)

1,016

-^{footnote F4}

Apr 7, 2026

Martin D. Madaus - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
Footnote F4 (price): For Footnote (4), see Remarks below.

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Common Stock

1,423,837^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Common Stock

1,146,829

-^{footnote F2,F4}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

160,565

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

159,339

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

768,639

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

151,071

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

152,529

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

123,801

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

118,877

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

106,300

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

117,829

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

117,801

-^{footnote F5}

Apr 7, 2026

Stephen P. Macmillan - Officer

Grant or award

Performance Stock Units

190,400

-^{footnote F7}

Apr 7, 2026

Stephen P. Macmillan - Officer

Derivative

Performance Stock Units

190,400

-^{footnote F7}

Footnote F1 (shares): Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
Footnote F5 (price): For Footnote (5), see Remarks below.
Footnote F7 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Common Stock

16,146^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

2,012

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,523

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,322

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,055

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,293

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,210

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F4}

Apr 7, 2026

Ludwig Hantson - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F4}

Footnote F1 (shares): Includes 3,695 restricted stock units, the settlement of which has been deferred pursuant to Hologic's Deferred Equity Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,396

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

6,523

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

7,322

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,055

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Common Stock

6,626

-^{footnote F1,F2}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Common Stock

15,370

-^{footnote F1,F3}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,293

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,210

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

4,536

-^{footnote F4}

Apr 7, 2026

Charles J. Dockendorff - Director

Derivative

Non-qualified Stock Option (Right to Buy)

5,535

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F2 (price): At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award… Full note on SEC EDGAR
Footnote F3 (price): As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
Footnote F4 (price): For Footnote (4), see Remarks below.

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Common Stock

17,964^{footnote F1}

-^{footnote F2,F3}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

10,861

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

7,505

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

7,132

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,382

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,509

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Non-qualified Stock Option (Right to Buy)

3,505

-^{footnote F4}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Grant or award

Performance Stock Units

5,665

-^{footnote F6}

Apr 7, 2026

Benjamin Jordan Cohn - Officer

Derivative

Performance Stock Units

5,665

-^{footnote F6}

Footnote F1 (shares): Includes 80 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned… Full note on SEC EDGAR
Footnote F3 (price): At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and… Full note on SEC EDGAR
Footnote F4 (price): For Footnote (4), see Remarks below.
Footnote F6 (price): Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of… Full note on SEC EDGAR

Feb 27, 2026

Anne M. Liddy - Officer

Tax withholding / forfeiture

Common Stock

185^{footnote F1}

$75.36

$14K

Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Feb 26, 2026

Amy McBride Wendell - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Stacey D. Stewart - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Christiana Stamoulis - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Nanaz Mohtashami - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Wayde D. McMillan - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Martin D. Madaus - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Ludwig Hantson - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 26, 2026

Charles J. Dockendorff - Director

Grant or award

Common Stock

3,190^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
Footnote F2 (price): Restricted stock units are settled in shares of common stock on a one-for-one basis.

Feb 10, 2026

Mark W. Horvath - Officer

Tax withholding / forfeiture

Common Stock

113^{footnote F1}

$75.15

$8K

Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Jan 30, 2026

Walt Diana de - Officer

Tax withholding / forfeiture

Common Stock

4,416^{footnote F1}

$74.93

$331K

Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Dec 12, 2025

Brandon Schnittker - Officer

Tax withholding / forfeiture

Common Stock

90^{footnote F1}

$75.00

$7K

Footnote F1 (shares): Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Laura FriedmanDemocrat, CA-30	Sale (partial)

Member

Type

Traded

Disclosed

Value range

Owner

Days to disclose

Filing

Laura FriedmanDemocrat, CA-30

Sale (partial)